Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Reverse Reaction

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43894   clinical trials with a EudraCT protocol, of which   7300   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    83 result(s) found for: Reverse Reaction. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2020-003078-36 Sponsor Protocol Number: 727258 Start Date*: 2020-09-14
    Sponsor Name:Aarhus University Hospital
    Full Title: The RAS-study A reverse and anatomical prosthesis shoulder study Can we improve the prophylactic profile of antibiotic treatment in shoulder prosthesis surgery? - A clinical microdialysis study as...
    Medical condition: Orthopedic infections
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004862 10021799 Infection and inflammatory reaction due to other internal orthopedic device, implant, and graft LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-003621-41 Sponsor Protocol Number: DESIRED Start Date*: 2016-12-05
    Sponsor Name:Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital
    Full Title: Desferal administration to improve the impaired reaction to hypoxia in diabetes (DESIRED) A randomised, double-blind, placebo-controlled, cross-over study
    Medical condition: The study will investigate the effect of deferoxamine on the impaired reaction to hypoxia in patients with diabetes mellitus type 1.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001224-33 Sponsor Protocol Number: COV-HCQ Start Date*: 2020-03-25
    Sponsor Name:Universitätsklinikum Tübingen
    Full Title: Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 – COVID-19
    Medical condition: Acute coronavirus disease 2019
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10053983 Corona virus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005759-18 Sponsor Protocol Number: CV43043 Start Date*: 2021-05-10
    Sponsor Name:F. Hoffmann La Roche Ltd.
    Full Title: A MULTICENTER, PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OUTPATIENT STUDY TO EVALUATE THE EFFICACY, SAFETY, AND ANTIVIRAL ACTIVITY OF RO7496998 AT-527 IN PATIENTS WITH MILD OR MODERAT...
    Medical condition: Mild to Moderate coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) DK (Prematurely Ended) FR (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004571-41 Sponsor Protocol Number: RBMinCovid19 Start Date*: 2021-02-23
    Sponsor Name:Cyxone AB
    Full Title: A Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety and Efficacy of Rabeximod Compared to Standard of Care in Patients With Moderate Coronavirus Disease (COVID-19)
    Medical condition: Coronavirus Disease (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Prematurely Ended) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003252-24 Sponsor Protocol Number: 53718678RSV2004 Start Date*: 2018-01-16
    Sponsor Name:Janssen Sciences Ireland UC
    Full Title: A Pilot Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ- 53718678 at Two Dose Le...
    Medical condition: Respiratory Syncytial Virus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10038717 Respiratory syncytial viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) SE (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-003002-17 Sponsor Protocol Number: 63623872FLZ2002 Start Date*: 2015-11-17
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult and Elderly H...
    Medical condition: Influenza A virus infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10022002 Influenza A virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) DE (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-000574-35 Sponsor Protocol Number: VIS410-201 Start Date*: 2015-04-27
    Sponsor Name:Visterra, Inc.
    Full Title: A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Antiviral Activity of a Single Intravenous Dose of VIS410 in Healthy Subjects after a Viral Ino...
    Medical condition: Influenza A (H1N1) infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10063211 Influenza A virus IgG LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001008-49 Sponsor Protocol Number: NV22155 Start Date*: 2016-09-30
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: A randomized, multicenter trial of oseltamivir doses of 75 mg for 5 or 10 days versus 150 mg for 5 or 10 days in influenza patients with pandemic (H1N1) 2009
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-001995-13 Sponsor Protocol Number: BREATH-19 Start Date*: 2020-05-15
    Sponsor Name:Fundación SEIMC-GESIDA
    Full Title: A multicentre, open-label clinical trial to evaluate the effectiveness and safety of intravenous tocilizumab for treating patients with COVID-19 pneumonia: the BREATH-19 Study
    Medical condition: COVID-19 pneumonia
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001827-15 Sponsor Protocol Number: CORTIVID Start Date*: 2020-04-30
    Sponsor Name:NAVARRABIOMED - FUNDACIÓN MIGUEL SERVET
    Full Title: EARLY TREATMENT OF PNEUMONIA COVID-19 WITH GLUCOCORTICOIDS. RANDOMIZED CONTROLLED CLINICAL TRIAL
    Medical condition: CoVid-19 pneumonia in early inflammatory phase (stage II).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001278-31 Sponsor Protocol Number: DEXA-COVID19 Start Date*: 2020-04-01
    Sponsor Name:Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES)
    Full Title: A comparative, randomised controlled trial for evaluating the efficacy of dexamethasone administration in the treatment of patients affected by COVID-19 with Acute Respiratory Distress Syndrome
    Medical condition: Acute respiratory distress syndrome (ARDS) in patients affected by COVID-19
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001026-22 Sponsor Protocol Number: 1813T0835 Start Date*: 2021-03-05
    Sponsor Name:Shionogi & Co., Ltd.
    Full Title: An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Baloxavir Marboxil 2% Granules after Administration of a Single Dose to Otherwise Healthy Pediatric Patient...
    Medical condition: Influenza
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000424-25 Sponsor Protocol Number: 1508175 Start Date*: 2016-04-12
    Sponsor Name:CHU Saint-Etienne
    Full Title: Low-molecular-weight heparin in constituted vascular intrauterine growth restriction. Randomized multicenter trial
    Medical condition: Intrauterine growth restriction (IUGR)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10022819 Intrauterine growth retardation LLT
    20.0 100000004868 10048489 Intrauterine growth retard LLT
    20.0 100000004868 10048488 Growth intrauterine retard LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015700-26 Sponsor Protocol Number: AH1N1-483-09THL Start Date*: 2009-10-16
    Sponsor Name:National Institute for Health and Welfare
    Full Title: Evaluation of a vaccination campaign with A(H1N1)v pandemic vaccines: a prospective cohort study. A(H1N1)v-pandemiarokotuskampanjan vaikutukset
    Medical condition: Influenza caused by the new A(H1N1)v influenza virus ("swine influenza")
    Disease: Version SOC Term Classification Code Term Level
    12.0 10022001 Influenza (epidemic) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2010-021033-30 Sponsor Protocol Number: H1N1-495-10THL Start Date*: 2010-09-14
    Sponsor Name:National Institute for Health and Welfare
    Full Title: Evaluation of the effectiveness of vaccination with 2009 H1N1 vaccines during influenza season 2010-11 2009 H1N1-influenssarokotteiden tehokkuus influenssakaudella 2010-11
    Medical condition: Influenza caused by the 2009 H1N1 influenza virus ("swine influenza")
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022001 Influenza (epidemic) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2020-005015-40 Sponsor Protocol Number: IVER-303 Start Date*: 2021-04-29
    Sponsor Name:Chemo Research S.L.
    Full Title: A multicentre, phase III, double-blind, randomised, parallel, placebo-controlled trial to assess efficacy and safety of early administration of Ivermectin during 3 consecutive days to prevent SARS ...
    Medical condition: Coronavirus disease (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002120-37 Sponsor Protocol Number: RESP301-002 Start Date*: 2020-06-16
    Sponsor Name:Thirty Respiratory Limited
    Full Title: An open-label, adaptive randomized, controlled multicenter study to evaluate the efficacy and safety of RESP301 plus standard of care (SOC) compared to SOC alone in hospitalized participants with C...
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10061986 SARS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-001467-82 Sponsor Protocol Number: P020.051 Start Date*: 2020-10-23
    Sponsor Name:Leiden University Medical Center
    Full Title: An Open-Label Study Evaluating Anti-Viral Effects of Voclosporin in SARS-CoV-2 Positive Kidney Transplant Recipients – the VOCOVID Study (COVID-19)
    Medical condition: SARS-CoV-2 infection in Kidney Transplant Recipients
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    21.1 100000004865 10052212 Organ transplant NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000455-39 Sponsor Protocol Number: C21-109-09 Start Date*: 2021-04-09
    Sponsor Name:Pharma Holdings AS
    Full Title: A double-blind, placebo-controlled, interventional parallel group study to evaluate the antiviral effect of a single nasal application of LTX-109 3% gel, in comparison to placebo gel, in subjects w...
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 15:32:54 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA